Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Casesinfectious-diseases

Paeds Cases · infectious-diseases

Explaining invasive fungal disease and central-line removal — OSCE

Communication and structured-discussion OSCE on explaining an episode of candidaemia and central-line removal to the parents of a neutropenic oncology child, covering why the line must come out, why an intravenous antifungal is needed, what the retinal examination is for, what the duration of therapy means, and how the next cycle will be protected by prophylaxis.

osce communication invasive candidiasis line removal5 min readVerification in progress

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
On this page
Study tools

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
Prompt
A 7-year-old with acute lymphoblastic leukaemia on day 12 of induction, profoundly neutropenic, grows Candida in blood cultures drawn through his central line. The candidate must explain to his parents why the line needs to come out, why an intravenous antifungal (an echinocandin or amphotericin) is needed, what the eye examination is for, and how the team will protect the next chemotherapy cycle with prophylaxis.

Candidate instructions (8-minute station)

You are the paediatric registrar on the oncology ward. A 7-year-old boy with acute lymphoblastic leukaemia, on day 12 of induction chemotherapy, has been profoundly neutropenic with a central venous catheter in situ. His blood cultures, drawn because of persistent fever, have grown Candida. The oncology team has decided to remove the central line and to start an intravenous antifungal. His parents are frightened: the fever was hard enough, and now they are being told their son has a "blood fungal infection," that his line must be pulled, and that he will need weeks of a new intravenous medicine. They are worried the line removal will derail his chemotherapy. [14]

Your tasks are: [2]

  1. Explain in plain language why a child with a central line and low immunity developed a fungal bloodstream infection, and why the line itself is part of the problem and must come out. [2] [14]
  2. Explain what the intravenous antifungal does, why it is given through a drip rather than by mouth at this stage, and what the team will watch for (kidney function, electrolytes, drug levels). [2]
  3. Explain why the ophthalmology team will examine his retinas, and what the two-week minimum duration means in terms of repeated blood cultures and follow-up. [14]
  4. Address the parents' worry about the chemotherapy, and explain how the team will protect the next cycle with prophylaxis. [1]

You are not expected to give exact antifungal doses to the parents; explain the plan in plain language and flag that any decision is made by the oncology and infectious-diseases teams with the parents' consent. [14]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References3ShowHide
  1. [1]Fisher BT; Zaoutis T; Dvorak CC; et al Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia. JAMA, 2019.PMID 31688884
  2. [2]Fisher BT; Zaoutis TE; Xiao R; et al Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children. J Pediatric Infect Dis Soc, 2021.PMID 34374424
  3. [14]Tissot F; Agrawal S; Pagano L; et al ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017.PMID 28011902
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousExplaining hand-foot-and-mouth disease — OSCEinfectious-diseasesNextExplaining isolation and an outbreak response — OSCEinfectious-diseases